NHS to offer second MenB vaccine after deadly Kent outbreak

NHS to Offer Second MenB Vaccine Following Kent Outbreak

Following a meningitis B outbreak in Kent, the NHS will provide a second dose of the vaccine to nearly 12,000 individuals who received the first shot. The second round of vaccinations is set to begin next week, targeting those potentially exposed to the disease. The outbreak resulted in two fatalities and 19 confirmed cases, prompting urgent action to protect at-risk populations.

Targeted Vaccination and Appointment Access

Initially, the vaccination campaign focused on university students and school pupils in the affected area, with later eligibility expanded to include other groups. Clinics in Canterbury, Faversham, and Ashford will administer the second dose, and appointments can be booked through an online system starting Monday. The NHS confirmed that multiple locations will be available for vaccinations.

Outbreak Origins and Expanded Reach

The outbreak is believed to have started at a local nightclub linked to the incident. Following the initial targeted approach, the program widened to include sixth form students from schools or colleges with confirmed cases. Preventative antibiotics were also distributed to a broader group, with long lines forming at the University of Kent over several days.

“The outbreak was unprecedented due to the rapid spread among people in a short time frame,” stated Health Secretary Wes Streeting.

UK Health Security Agency (UKHSA) declared a national incident to facilitate the allocation of resources, such as antibiotics. The second dose must be administered at least four weeks after the first but can be given later if needed. This marks a shift from the routine MenB vaccination program introduced in 2015 for infants, which did not initially cover teenagers.

Previously, UK health advisers deemed a catch-up campaign for teenagers cost-ineffective, opting instead for the MenACWY vaccine, which guards against four meningitis strains. However, the recent outbreak has prompted a reassessment of this decision by the Joint Committee on Vaccination and Immunisation (JCVI).